All News
Filter News
Found 11,786 articles
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
5/4/2023
Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors reported financial results and business highlights for the first quarter ended March 31, 2023.
-
Three Finalists Announced for the 2023 Bloom Burton Award
5/4/2023
Bloom Burton & Co. is pleased to announce the finalists for the 2023 Bloom Burton Award.
-
The regulatory decision marks a turning point in the RSV race in what’s expected to be a competitive space.
-
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
5/3/2023
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States.
-
Small Molecule Drug Discovery Market ($50.82Bn by 2027) Driven by Rare Diseases Segment | The Insight Partners
5/3/2023
The Insight Partners published latest research report on "Small Molecule Drug Discovery Market Size Report, Share, Growth & Trends Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapeutic Area; Process/Phase; and Geography”,
-
Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer
5/2/2023
Amphista Therapeutics announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer.
-
Japanese biopharma scoops up Iveric’s investigational drug for age-related blindness disease. The drug, which trails Apellis’ Syfovre, is awaiting FDA approval with a decision expected by August.
-
Galera Expands Commercial Leadership Team
5/1/2023
Galera Therapeutics, Inc. today announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective immediately.
-
Gene Bio Medical Announces Partnership with Prairie Hub for Pandemic Preparedness
4/28/2023
Gene Biotechnology Enterprises Ltd, doing business as Gene Bio Medical, is proud to announce its partnership with the Prairie Hub for Pandemic Preparedness as a key commercialization partner.
-
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US
4/27/2023
A new antidepressant drug candidate being developed by researchers at Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) is said to have mechanistic activity and therapeutic features that set it apart from almost all of the currently approved antidepressants in the U.S.
-
At 4% CAGR, Antibiotics Market to Reach $59.25 Billion, Globally, by 2028 – The Insight Partners
4/27/2023
The Insight Partners published latest research report on "Antibiotics Market Share Report, Size, Trends, Growth & Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class; Action Mechanism, and Geography" the global market size was valued at USD 44,111.31 million in 2020 and is projected to reach USD 59,253.24 million in 2028; it is expected to grow at a CAGR of 4% during 2021–2028.
-
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including at the 2023 ASCO Annual Meeting
4/26/2023
Zentalis ® Pharmaceuticals, Inc. announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, June 2-6, 2023.
-
VBI Vaccines Appoints Vaughn Himes to Board of Directors
4/25/2023
VBI Vaccines Inc. today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors.
-
GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
4/24/2023
GRI Bio, Inc. today announced the appointments of David Szekeres, Roelof Rongen, MSE, MBA, and Camilla V. Simpson, M.Sc. to the Company’s Board of Directors.
-
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
4/20/2023
Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.
-
Respiratory Inhalers Market to Grow at 5.7% CAGR to Reach $43.44Bn by 2028 - The Insight Partners
4/20/2023
The Insight Partners published latest research report on "Respiratory Inhalers Market Size Report, Share, Trends, Growth and Revenue Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, and Disease Indication" the global market size is expected to grow from USD 31,144.56 million in 2022 to USD 43,446.19 million by 2028; it is estimated to record a CAGR of 5.7% from 2022 to 2028.
-
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
4/18/2023
Surface Oncology today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.
-
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
4/17/2023
ReCode Therapeutics announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
-
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
4/17/2023
ZentalisTM Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announces preclinical data that supports CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib, the Company’s potentially first-in-class Wee1 inhibitor product candidate.
-
Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources
4/13/2023
Jasper Therapeutics, Inc. announced the appointment of Matthew Ford as the Company’s Vice President, Human Resources.